Kong X, Li F, Wang Y
J Cell Mol Med. 2025; 29(5):e70453.
PMID: 40032652
PMC: 11875779.
DOI: 10.1111/jcmm.70453.
Fu Y, Yang X, Li S, Ma C, An Y, Cheng T
Nat Commun. 2025; 16(1):1640.
PMID: 39952932
PMC: 11828908.
DOI: 10.1038/s41467-025-56735-8.
Rohm D, Black J, McCutcheon S, Barrera A, Berry S, Morone D
Cell Genom. 2025; 5(2):100770.
PMID: 39947136
PMC: 11872474.
DOI: 10.1016/j.xgen.2025.100770.
Arvidsson E, Lobo D, Sabarese E, Duarte F, Nobre R, Quintino L
Front Bioeng Biotechnol. 2025; 13:1336313.
PMID: 39917018
PMC: 11799263.
DOI: 10.3389/fbioe.2025.1336313.
Zhao X, Yang L, Li P, Cheng Z, Jia Y, Luo L
Mol Ther Nucleic Acids. 2025; 36(1):102428.
PMID: 39897580
PMC: 11787013.
DOI: 10.1016/j.omtn.2024.102428.
Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges.
Sugiokto F, Li R
Viruses. 2025; 17(1).
PMID: 39861899
PMC: 11768851.
DOI: 10.3390/v17010110.
Proline exacerbates hepatic gluconeogenesis via paraspeckle-dependent mRNA retention.
Zhao Y, Chai X, Peng J, Zhu Y, Dong R, He J
Nat Metab. 2025; 7(2):367-382.
PMID: 39820557
DOI: 10.1038/s42255-024-01206-5.
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
Fleming T, Antoszewski M, Lambo S, Gundry M, Piussi R, Wahlster L
bioRxiv. 2025; .
PMID: 39803492
PMC: 11722404.
DOI: 10.1101/2024.12.30.630680.
Establishment of a CRISPR-Based Lentiviral Activation Library for Transcription Factor Screening in Porcine Cells.
Liang Y, Yao X, Han J, Wang J, Zhang X, Zhao D
Animals (Basel). 2025; 15(1.
PMID: 39794961
PMC: 11718943.
DOI: 10.3390/ani15010019.
Binding of to dystrophin impairs the membrane trafficking of Nav1.5 protein and increases ventricular arrhythmia susceptibility.
Xue G, Yang J, Zhang Y, Yang Y, Zhang R, Li D
Elife. 2025; 12.
PMID: 39773412
PMC: 11706603.
DOI: 10.7554/eLife.89690.
Chemical engineering of CRISPR-Cas systems for therapeutic application.
Barber H, Pater A, Gagnon K, Damha M, OReilly D
Nat Rev Drug Discov. 2024; 24(3):209-230.
PMID: 39690326
DOI: 10.1038/s41573-024-01086-0.
Generation of an inducible dCas9-SAM human PSC line for endogenous gene activation.
Petazzi P, Gutierrez-Aguera F, Roca-Ho H, Castano J, Bueno C, Alvarez N
Front Cell Dev Biol. 2024; 12:1484955.
PMID: 39676795
PMC: 11638181.
DOI: 10.3389/fcell.2024.1484955.
Synthetic lethal strategies for the development of cancer therapeutics.
Ngoi N, Gallo D, Torrado C, Nardo M, Durocher D, Yap T
Nat Rev Clin Oncol. 2024; 22(1):46-64.
PMID: 39627502
DOI: 10.1038/s41571-024-00966-z.
Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems.
Brokso A, Bendixen L, Famme S, Mikkelsen K, Jensen T, Bak R
Mol Ther. 2024; 33(1):71-89.
PMID: 39563029
PMC: 11764084.
DOI: 10.1016/j.ymthe.2024.11.024.
Emerging Gene-editing nano-therapeutics for Cancer.
Nujoom N, Koyakutty M, Biswas L, Rajkumar T, Nair S
Heliyon. 2024; 10(21):e39323.
PMID: 39524822
PMC: 11550658.
DOI: 10.1016/j.heliyon.2024.e39323.
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles.
Degtev D, Bravo J, Emmanouilidi A, Zdravkovic A, Choong O, Touza J
Nat Commun. 2024; 15(1):9173.
PMID: 39511150
PMC: 11544209.
DOI: 10.1038/s41467-024-53418-8.
Development of compact transcriptional effectors using high-throughput measurements in diverse contexts.
Tycko J, Van M, Aradhana , DelRosso N, Ye H, Yao D
Nat Biotechnol. 2024; .
PMID: 39487265
DOI: 10.1038/s41587-024-02442-6.
Development of artificial transcription factors and their applications in cell reprograming, genetic screen, and disease treatment.
Sang Y, Xu L, Bao Z
Mol Ther. 2024; 32(12):4208-4234.
PMID: 39473180
PMC: 11638881.
DOI: 10.1016/j.ymthe.2024.10.029.
Strategies for improving the genome-editing efficiency of class 2 CRISPR/Cas system.
Wang L, Han H
Heliyon. 2024; 10(19):e38588.
PMID: 39397905
PMC: 11471210.
DOI: 10.1016/j.heliyon.2024.e38588.
AAV-mediated gene therapies by miniature gene editing tools.
Kong X, Li T, Yang H
Sci China Life Sci. 2024; 67(12):2540-2553.
PMID: 39388062
DOI: 10.1007/s11427-023-2608-5.